What type of breast cancer is lapatinib effective against? What type of patients is it suitable for?

Lapatinib is a targeted drug mainly used to treat patients with HER2-positive breast cancer. HER2 (human epidermal growth factor receptor 2) is a protein highly expressed in breast cancer and is involved in cell proliferation and growth. Approximately 15% to 20% of breast cancer patients show amplification or overexpression of the HER2 gene, and these patients generally have higher recurrence rates and poor prognosis. Lapatinib plays a therapeutic role by inhibiting the activity of the HER2 receptor and inhibiting the proliferation of tumor cells.

Lapatinib is mainly suitable for patients with HER2positive, locally advanced or metastatic breast cancer, especially when traditional chemotherapy or other HER2 targeted therapies (such as trastuzumab) are ineffective or intolerable. For these patients, lapatinib can significantly improve efficacy as a second- or third-line treatment. Lapatinib can not only effectively inhibit the HER2 receptor, but also further enhance the anti-tumor effect by inhibiting other related targets such as EGFR (epidermal growth factor receptor).

In addition, lapatinib is often used in combination with chemotherapy drugs such as capecitabine to treat patients with HER2-positive breast cancer that has metastasized. Studies have shown that combined treatment with lapatinib and capecitabine can significantly improve the efficacy and prolong the progression-free survival of patients. This combination program is especially suitable for patients whose previous treatments have failed or whose disease has relapsed, and can help control the disease and improve their quality of life.

Although lapatinib has a good effect on HER2 positive breast cancer patients, it is not suitable for all breast cancer patients. For patients with HER2 negative breast cancer, lapatinib is generally ineffective because its main effect is to exert anti-tumor effects by inhibiting the HER2 receptor. Therefore, before treatment with lapatinib, patients need to have their HER2 status tested to determine whether they are suitable for this drug. For the right patient population, lapatinib offers an effective treatment option, especially when other treatments have failed.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html